With $7 million from the Patient-Centered Outcomes Research Institute, seven opioid treatment programs announced entry into an ongoing study of telemedicine for treatment of hepatitis C.
“The concept of the telemedicine model is that we are taking advantage of the ambience of the environment within the methadone programs, where patients generally feel more comfortable than conventional health care settings,” Andrew H. Talal, MD, from the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo, told Healio Gastroenterology and Liver Disease. “We’re taking advantage of that to integrate HCV treatment into that already existing relationship.”
This activity is supported by educational grants from AbbVie, Inc.; Pfizer, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2019 Healio All Rights Reserved.